EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β‐Blockers to PI3K / AKT / mTOR Inhibitors

Hubert Arasiewicz iD, Michal Dec

Journal of Cellular and Molecular Medicine · 2026

DOI: 10.1111/jcmm.71103 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Cellular and Molecular Medicine, 2026. Verfasst von Hubert Arasiewicz und 1 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Department of Pediatric Dermatology and Vascular Anomalies, Faculty of Medical Sciences in Katowice, Medical University of Silesia, John Pau…. Hauptthemen laut MEDLINE: Hemangioma, Vascular Malformations, Proto-Oncogene Proteins c-akt, Adrenergic beta-Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular tumours and malformations encompass infantile hemangiomas (IHs) and genetically driven vascular malformations with distinct natural histories and therapeutic vulnerabilities. The discovery that the non‐selective beta‐blocker propranolol induces rapid regression of proliferating IHs established the first widely adopted systemic pharmacologic therapy in vascular anomaly care and provided a clinical proof‐of‐concept that targeting lesion‐specific endothelial biology can alter disease course. In parallel, recurrent somatic variants affecting PI3K/AKT/mTOR (e.g., PIK3CA, TEK/TIE2, AKT1) and RAS/MAPK (e.g., KRAS, NRAS) signalling have reframed many malformations as mosaic disorders amenable to targeted inhibition with agents such as sirolimus, alpelisib, AKT inhibitors and MEK inhibitors. This review synthesizes translational mechanisms, clinical evidence and safety considerations for beta‐blockers and emerging targeted therapies, emphasizing lesion phenotype, timing of intervention and molecular stratification as determinants of response. We highlight current limitations, including toxicity, durability and pathway escape, and outline future directions for precision therapy and genotype‐guided trial design in vascular anomalies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HemangiomaVascular MalformationsProto-Oncogene Proteins c-aktAdrenergic beta-AntagonistsMTOR InhibitorsMolecular Targeted TherapyProtein Kinase InhibitorsHumansTOR Serine-Threonine KinasesSignal TransductionPhosphatidylinositol 3-KinasesAnimalsInfant

Stichwörter der Autor:innen

PI3K/AKT/mTORRAS/MAPKinfantile hemangiomaprecision medicinetargeted therapyvascular malformations

Substanzen

Proto-Oncogene Proteins c-aktAdrenergic beta-AntagonistsTOR Serine-Threonine KinasesMTOR InhibitorsPhosphatidylinositol 3-KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Clinical Department of Pediatric Dermatology and Vascular Anomalies, Faculty of Medical Sciences in Katowice, Medical University of Silesia, John Paul II Children's and Family Health Center, Sosnowiec, Silesian Voivodes…

ORCID-Profile: Hubert Arasiewicz

Zitieren

APA

Arasiewicz, H., & Dec, M. (2026). Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β‐Blockers to PI3K / AKT / mTOR Inhibitors. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.71103

Vancouver

Arasiewicz H, Dec M. Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β‐Blockers to PI3K / AKT / mTOR Inhibitors. Journal of Cellular and Molecular Medicine. 2026. doi:10.1111/jcmm.71103

BibTeX
@article{Arasiewicz2026,
  author = {Arasiewicz, Hubert and Dec, Michal},
  title = {Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β‐Blockers to PI3K / AKT / mTOR Inhibitors},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2026},
  doi = {10.1111/jcmm.71103}
}
Kostenlos starten →